EC approves tafasitamab combo in relapsed follicular lymphoma
The European Commission approved tafasitamab (Minjuvi) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL) grade
The European Commission approved tafasitamab (Minjuvi) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma (FL) grade
“We have gone from having R-CHOP and chemotherapy in the second link to to having an embarrassment of riches, basically a wealth of
In this SOHO Insider interview from the American Society of Hematology Annual Meeting & Exposition, Lore Gruenbaum, PhD, chief scientific officer at Blood
The United States Food and Drug Administration selected the supplemental Biologics License Application for teclistamab (TECVAYLI) plus daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) to
LOS ANGELES—SOHO Insider, the official media platform of the Society of Hematologic Oncology (SOHO) has announced the launch of its Virtual Community Oncology
The FDA has granted priority review nivolumab in combination with doxorubicin, vinblastine and dacarbazine (AVD) for adult and pediatric patients who are 12
Dr. Nina Shah leads a discussion at 2:00 pm CST on November 10, 2026, on how can pharma engage with community oncologists.
Dr. Shakira Grant leads a discussion at 1:00 pm CST on October 13, 2026, on AI impacting pathology and treatment decisions.
Dr. Hans Lee leads a discussion at 12:30 pm CST on September 2, 2026, on increasing US representation in global clinical trials.
Dr. Marin Xavier leads a discussion at 3:00 pm CST on August 11, 2026, on integrating new evidence into everyday practice.